Inventiva reports 2024 Third Quarter Financial Information¹
Combined General Meeting of December 11, 2024 - Availability of the preparatory documents
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
Inventiva S.A. (NASDAQ: IVA) is now covered by analysts at UBS Group AG. They set a "neutral" rating and a $3.00 price target on the stock.
Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH